Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenetic Biosciences, Inc. - Common Stock
(NQ:
XBIO
)
2.165
+0.045 (+2.12%)
Delayed Quote
Updated: 3:47 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenetic Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 23, 2025
Via
Benzinga
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Via
ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
April 09, 2025
Via
ACCESS Newswire
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
March 26, 2025
Via
ACCESS Newswire
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
March 19, 2025
Via
ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
December 17, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
November 22, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
November 13, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
March 13, 2025
Via
ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
February 27, 2025
Via
ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
December 16, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
December 05, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
November 21, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
November 07, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
May 22, 2024
Via
ACCESSWIRE
Xenetic Biosciences: Q3 Earnings Insights
↗
November 10, 2023
Via
Benzinga
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
November 12, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
October 22, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
October 17, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
↗
September 30, 2024
Via
Benzinga
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
September 11, 2024
Via
ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024
↗
August 13, 2024
XBIO stock results show that Xenetic Biosciences met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024
Via
ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024
↗
May 09, 2024
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
↗
March 22, 2024
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
March 22, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
January 17, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
December 05, 2023
Via
Benzinga
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
November 10, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
